ArticleBMC psychiatry2026
Neuroinflammatory-related biomarkers and psychiatric symptom changes in substance use disorder: a South African cohort study.
Article in BMC psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSubstance use disorder (SUD) is a debilitating neuropsychiatric condition characterized by persistent compulsive drug use and associated cognitive and psychiatric impairments. Emerging evidence suggests that neuroinflammatory pathways contribute to the pathophysiology of SUD. However, the relationships between neuroinflammatory-related biomarkers and psychiatric symptomatology in SUD remain poorly understood. This study aimed to investigate neuroinflammatory-related biomarkers and their association with psychiatric symptom changes in individuals with SUD.
methodsParticipants with SUD (N = 100) at three local facilities in the North West Province of South Africa were enrolled. At baseline and following three weeks of treatment, psychiatric symptoms were assessed using the Brief Psychiatric Rating Scale (BPRS). Serum levels of superoxide dismutase (SOD), glutathione (GSH), glutathione disulphide (GSSG), tryptophan, kynurenine (KYN), kynurenic acid (KYNA), serotonin (5-HT), 5-hydroxyindoleacetic acid (5-HIAA), cortisol and serum S100 calcium-binding protein B (S100B) were measured.
resultsOver the 3-week treatment period BPRS scores and serum levels of tryptophan, 5-HT, 5-HIAA, KYN, KYNA, cortisol and GSH decreased, whereas SOD, S100B and GSSG levels increased. Baseline BPRS correlated with baseline serum levels of 5-HIAA, KYNA and GSSG. A decrease in BPRS correlated with baseline levels of 5HIAA, KYN and KYNA, as well as with 3-week changes in levels of select biomarkers (∆tryptophan, ∆5-HT, ∆5-HIAA, ∆KYN, ∆KYNA, ∆GSSG and ∆cortisol).
conclusionThe results suggest that baseline 5-HIAA, KYN and KYNA may predict psychiatric symptom improvement whereas tryptophan, 5-HT, 5-HIAA, KYN, KYNA, GSSG and cortisol may explain the neurobiological basis of changed psychiatric symptomatology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.